KR20200012939A - 과민성 방광의 치료를 위한 비베그론의 투약 - Google Patents

과민성 방광의 치료를 위한 비베그론의 투약 Download PDF

Info

Publication number
KR20200012939A
KR20200012939A KR1020197038521A KR20197038521A KR20200012939A KR 20200012939 A KR20200012939 A KR 20200012939A KR 1020197038521 A KR1020197038521 A KR 1020197038521A KR 20197038521 A KR20197038521 A KR 20197038521A KR 20200012939 A KR20200012939 A KR 20200012939A
Authority
KR
South Korea
Prior art keywords
dose
per day
bibegron
dosage
vibegron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038521A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 씨. 피씨텔리
폴 머드
Original Assignee
유로반트 사이언시즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로반트 사이언시즈 게엠베하 filed Critical 유로반트 사이언시즈 게엠베하
Priority to KR1020257019594A priority Critical patent/KR20250095747A/ko
Publication of KR20200012939A publication Critical patent/KR20200012939A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020197038521A 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 투약 Ceased KR20200012939A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257019594A KR20250095747A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 투약

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762516013P 2017-06-06 2017-06-06
US62/516,013 2017-06-06
US201862635310P 2018-02-26 2018-02-26
US62/635,310 2018-02-26
US201862637949P 2018-03-02 2018-03-02
US62/637,949 2018-03-02
PCT/IB2018/054070 WO2018224990A1 (en) 2017-06-06 2018-06-06 Dosing of vibegron for treatment of overactive bladder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257019594A Division KR20250095747A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 투약

Publications (1)

Publication Number Publication Date
KR20200012939A true KR20200012939A (ko) 2020-02-05

Family

ID=62815098

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197038521A Ceased KR20200012939A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 투약
KR1020257019594A Pending KR20250095747A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 투약

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257019594A Pending KR20250095747A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 투약

Country Status (9)

Country Link
US (2) US20210077496A1 (https=)
EP (1) EP3634488A1 (https=)
JP (2) JP7670461B2 (https=)
KR (2) KR20200012939A (https=)
CN (1) CN110869053A (https=)
AU (2) AU2018282105A1 (https=)
CA (1) CA3064973A1 (https=)
MX (1) MX2023000187A (https=)
WO (1) WO2018224990A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250051257A (ko) 2023-10-10 2025-04-17 (주)케이아트휀스 지주파이프 롤포밍 장치

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
CA3085745A1 (en) * 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
KR102940911B1 (ko) 2018-12-05 2026-03-17 유로반트 사이언시즈 게엠베하 과민성 방광 증상의 치료를 위한 비베그론
EP3941473A1 (en) * 2019-03-18 2022-01-26 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
US20240050457A1 (en) * 2020-12-22 2024-02-15 Urovant Sciences Gmbh Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
NZ599233A (en) * 2009-10-07 2013-04-26 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
WO2013062878A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
PL2968269T3 (pl) 2013-03-15 2020-03-31 Merck Sharp & Dohme Corp. Sposób przygotowywania agonistów beta-3 i produktów pośrednich
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250051257A (ko) 2023-10-10 2025-04-17 (주)케이아트휀스 지주파이프 롤포밍 장치

Also Published As

Publication number Publication date
US20230218624A1 (en) 2023-07-13
EP3634488A1 (en) 2020-04-15
CN110869053A (zh) 2020-03-06
CA3064973A1 (en) 2018-12-13
MX2023000187A (es) 2023-02-09
US20210077496A1 (en) 2021-03-18
WO2018224990A1 (en) 2018-12-13
KR20250095747A (ko) 2025-06-26
JP2023058635A (ja) 2023-04-25
AU2018282105A1 (en) 2019-12-12
JP2020523334A (ja) 2020-08-06
AU2024204108A1 (en) 2024-07-04
JP7670461B2 (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
US20260014158A1 (en) Use of vibegron to treat overactive bladder
JP7670461B2 (ja) 過活動膀胱の治療のためのビベグロンの投薬
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
EP4545072A2 (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
US20210196720A1 (en) Use of vibegron to treat pain associated with irritable bowel syndrome
JP6682533B2 (ja) 多汗症を治療するための方法
HK40114255A (en) Use of vibegron to treat overactive bladder
EA045454B1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
CN111526875A (zh) 用于治疗骨关节炎疼痛的mPGES-1抑制剂
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
TW202444359A (zh) 用於向患有肝損傷的患者施用帕妥索汀的組合物和方法
HK40084818B (zh) 治疗慢性肾病的方法和药物组合物
HK40025703A (en) Mpges-1 inhibitor for the treatment of osteoarthritis pain

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210604

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240102

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240708

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241209

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20250118

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20250118

X601 Decision of rejection after re-examination